---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044855"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:28:09.622468+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience Q1 revenue rises 54% to $718K; net loss narrows to $735K

## Summary
- Net product sales of $718K for Q1 FY2024, up $251K from $467K in Q1 FY2023.
- Net loss improved to $735K from $993K year-over-year; EPS unchanged at ($0.01).
- Excluding share-based compensation, net loss was $655K vs $909K.
- CEO cites sales initiatives paying off; VP of Sales highlights competitive advantage in food safety.
- Business update stresses customer focus, IoT/SaaS innovation, and 100 years of combined staff experience.

## SEC filing metadata
- accession: 0001493152-23-044855
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315223044855/0001493152-23-044855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315223044855/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044855
- JSON: https://secwatch.observer/filing/0001493152-23-044855.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044855.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.